Maintenance treatment of bipolar disorder: Applying research to clinical practice

Journal of Psychiatric Practice

Volumn 12, Issue 5, 2006, Pages 283-299

  Chou, James C Y ^a,c   Fazzio, Lydia ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

Anticonvulsant; Antipsychotic; Aripiprazole; Bipolar disorder; Carbamazepine; Divalproex; Lamotrigine; Lithium; Maintenance treatment; Olanzapine

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CARBAMAZEPINE; IMIPRAMINE; LAMOTRIGINE; LITHIUM; METHYLENE BLUE; NIMODIPINE; OLANZAPINE; PLACEBO; VALPROATE SEMISODIUM;

AKATHISIA; ALOPECIA; BIPOLAR DISORDER; CLINICAL PRACTICE; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; HUMAN; HYPERCHOLESTEROLEMIA; INFECTION; MAINTENANCE THERAPY; MANIA; PROLACTIN BLOOD LEVEL; QT PROLONGATION; RASH; RELAPSE; REVIEW; SEDATION; SIDE EFFECT; SURVIVAL; TINNITUS; TREMOR; WEIGHT GAIN;

EID: 33748957214     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/00131746-200609000-00003     Document Type: Review

References (70)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition, text revision. Washington, DC: American Psychiatric Association; 2000.
2. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59:530-7.
3. Baastrup PC, Poulsen JC, Schou M, et al. Prophylactic lithium: Double blind discontinuation in manic-depressive and recurrent depressive disorders. Lancet 1970;2:326-30.
4. Coppen A, Nogubra R, Bailey J, et al. Prophylactic lithium in affective disorders. Lancet 1971;2:275-9.
5. Cundall RL, Brooks PW, Murray LG. A controlled evaluation of lithium prophylaxis in affective disorders. Psychol Med 1972;2:308-11.
6. Hullin RP, McDonald R, Allsopp MNE. Prophylactic lithium in recurrent affective disorders. Lancet 1972;1:1044-6.
7. Dunner DL, Stallone F, Fieve RR. Lithium carbonate and affective disorders, V: A double-blind study of prophylaxis of depression in bipolar illness. Arch Gen Psychiatry 1976;33:117-20.
8. Melia PI. Prophylactic lithium: A double-blind trial in recurrent affective disorders. Br J Psychiatry 1970;116:621-4.
9. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003;60:392-400.
10. Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003;64:1013-24.
11. Prien RF, Caffey EM, Klett CJ. Prophylactic efficacy of lithium carbonate in manic-depressive illness: Report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group. Arch Gen Psychiatry 1973;28:337-41.
12. Prien RF, Klett CJ, Caffey EM. Lithium prophylaxis in recurrent affective illness. Am J Psychiatry 1974;131:198-203.
13. Prien RF, Caffey EM, Klett CJ. Factors associated with treatment success in lithium carbonate prophylaxis. Arch Gen Psychiatry 1974;31:189-92.
14. Prien RF, Klett CJ, Caffey EM. Lithium carbonate and imipramine in prevention of affective episodes: A comparison in recurrent affective illness. Arch Gen Psychiatry 1973;29:420-5.
15. Okuma T, Inanaga K, Otsuki S, et al. A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Psychopharmacology 1981;73:95-6.
16. Kane JM, Quitkin RF, Rifkin A, et al. Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: A prospective, placebo-controlled comparison. Arch Gen Psychiatry 1982;39:1065-9.
17. Prien Rf, Kupfer DJ, Mansky PA, et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Arch Gen Psychiatry 1984;41:1096-104.
18. Shapiro Dr, Quitkin FM, Fleiss JL. Response to maintenance therapy in bipolar illness: Effect of index episode. Arch Gen Psychiatry 1989;46:401-5.
19. Naylor GJ, Martin B, Hopwood E, et al. A two-year double-blind crossover trial of the prophylactic effect of methylene blue in manic-depressive psychosis. Society of Biological Psychiatry 1986;21:915-20.
20. Giannini AJ, Taraszewski R, Loiselle RH. Verapamil and lithium in maintenance therapy of manic patients. J Clin Pharmacol 1987;27:980-2.
21. Hartong EG, Moleman P, Hoogduin CAL, et al. Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. J Clin Psychiatry 2003;64:144-51.
22. Pazzaglia PJ, Post RM, Ketter TA, et al. Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation. Psychiatry Res 1993;49:257-72.
23. Pazzaglia PJ, Post RM, Ketter TA, et al. Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness. J Clin Psychopharmacol 1998;18:404-13.
24. Gelenberg AJ, Kane JM, Keller MB, et al. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar depression. N Engl J Med 1989;321:1489-93.
25. Denicoff KD, Smith-Jackson EE, Disney ER, et al. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997; 58:470-8.
26. Perlis RH, Sachs GS, Lafer B, et al. Effect of abrupt change from standard to low serum levels of lithium: A reanalysis of double-blind lithium maintenance data. Am J Psychiatry 2002;159:1155-9.
27. Kramlinger KG, Post RM. Adding lithium carbonate to carbamazepine: Antimanic efficacy in treatment-resistant mania. Acta Psychiatr Scand 1989;79:378-85.
28. Quitkin FM, Kane J, Rifkin A, et al. Prophylactic lithium carbonate with and without imipramine for bipolar patients: A double-blind study. Arch Gen Psychiatry 1981;38:902-7.
29. Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000;57:481-9.
30. Calabrese JR, Suppes T, Bowden CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 2000;61:841-50.
31. Keck PE Jr, Calabrese JR, McQuade RD, et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006;67:626-37.
32. Tohen M, Chengappa NR, Suples T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004;184:337-45.
33. Tohen M, Calabrese JR, Sachs GS, et al. Olanzapine versus placebo in the prevention of relapse in bipolar disorder. Am J Psychiatry 2006;163:247-56.
34. Tondo L, Baldessarini RJ, Hennen J. Lithium and suicide risk in bipolar disorder. Primary Psychiatry 1999;6:51-6.
35. Baldessarini RJ, Tondo L, Viguera AC. Discontinuing lithium maintenance treatment in bipolar disorders: Risks and implications. Bipolar Disorders 1999;1:17-24.
36. Baldessarini RJ, Tondo L, Hennen J. Lithium treatment and suicide risk in major affective disorders: Update and new findings. J Clin Psychiatry 2003; 64(suppl 5):44-52.
37. Goodwin FK, Fireman B, Simon GE, et al. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 2003;290:1467-73.
38. Baldessarini RJ, Tondo L, Hennen J. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. J Clin Psychiatry 1999;60(Suppl 2):77-84.
39. Cipriani A, Pretty H, Hawton K, et al. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: A systematic review of randomized trials. Am J Psychiatry 2005;162:1805-19.
40. Thies-Flechtner K, Muller-Oerlinghausen B, Seibert W, et al. Effect of prophylactic treatment on suicide risk in patients with major affective disorders: Data from a randomized prospective trial. Pharmacopsychiatry 1996;29:103-7.
41. Goodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004;65:432-41.
42. Gyulai L, Bowden CL, McElroy SL, et al. Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 2003;28:1374-82.
43. Joffe H, Cohen LS, Suppes T, et al.Valproate is associated with new-onset oligomenorrhea with hyperandrogenism in women with bipolar disorder. Biol Psychiatry 2006;59:1078-86.
44. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry 2002;159(suppl):1-50.
45. Bauer MS, Mitchner L. What is a "mood stabilizer"? An evidence-based response. Am J Psychiatry 2004;161:3-18.
46. Bowden CL. New concepts in mood stabilization: Evidence for the effectiveness of valproate and lamotrigine. Neuropsychopharmacol 1998;19:194-9.
47. Sachs GS. Bipolar mood disorder: Practical strategies for acute and maintenance phase treatment. J Clin Psychopharmacol 1996;16(2 Suppl 1):32S-47S.
48. Suppes T, Baldessarini RJ, Faedda GL, et al. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991;48:1082-8.
49. Calabrese JR, Goldberg JF, Ketter TA, et al. Recurrence in bipolar I disorder: A post hoc analysis excluding relapses in two double-blind maintenance studies. Biol Psychiatry 2006;59:1061-4.
50. Blanco C, Laje G, Olfson M, et al. Trends in the treatment of bipolar disorder by outpatient psychiatrists. Am J Psychiatry 2002;159:1005-10.
51. Preskorn SH, Lacey RL. Polypharmacy: When is it rational? J Pract Psychiatry Behav Health 1995;1:92-8.
52. Wehr TA, Sack DA, Rosenthal NE, et al. Rapid cycling affective disorder: Contributing factors and treatment responses in 51 patients. Am J Psychiatry 1988;145:179-84.
53. Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry 1994; 151:549-50.
54. Leverich GS, Altshuler LL, Frye MA, et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry 2006;163:232-9.
55. Altshuler L, Suppes T, Black D, et al. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry 2003;160:1252-62.
56. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264:2511-8.
57. Grant BF, Stinson FS, Dawson DA, et al. Co-occurrence of 12-month alcohol and drug use disorders and personality disorders in the United States: Results From the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2004;61:361-8.
58. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:593-602.
59. Feinman JA, Dunner DK. The effect of alcohol and substance abuse on the course of bipolar affective disorder. J Affect Disord 1996;37:43-9.
60. Nolen WA, Luckenbaugh DA, Altshuler LL, et al. Correlates of 1-year prospective outcome in bipolar disorder: Results from the Stanley Foundation Bipolar Network. Am J Psychiatry 2004;161:1447-54.
61. Weiss RD, Ostacher MJ, Otto MW, et al. Does recovery from substance use disorder matter in patients with bipolar disorder? J Clin Psychiatry 2005;66:730-5.
62. Sherwood Brown E, Suppes T, Adinoff B, et al. Drug abuse and bipolar disorder: Comorbidity or misdiagnosis? J Affect Disord 2001;65:105-15.
63. Dalton EJ, Cate-Carter TD, Mundo E, et al. Suicide risk in bipolar patients: The role of co-morbid substance use disorders. Bipolar Disord. 2003;5:58-61.
64. Sonne SC, Brady KT, Morton WA, et al. Substance abuse and bipolar affective disorder. J Nerv Ment Dis 1994;182:349-52.
65. Haro JM, van Os J, Vieta E, et al. Evidence for three distinct classes of typical, psychotic and dual mania: Results from the EMBLEM study. Acta Psychiatr Scand 2006;113:112-20.
66. McIntyre RS, Konarski JZ, Yatham LN. Comorbidity in bipolar disorder: A framework for rational treatment selection. Hum Psychopharmacol 2004;19:369-86.
67. O'Brien CP, Charney DS, Lewis L, et al. Priority action to improve the care of persons with co-occurring substance abuse and other mental disorders: A call to action. Biol Psychiatry 2004;56:703-13.
68. Kosten TR, Kosten TA. New medication strategies for comorbid substance abuse and bipolar affective disorders. Biol Psychiatry 2004;56:771-7.
69. Salloum IM, Cornelius JR, Daley DC, et al. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: A double-blind placebo-controlled study. Arch Gen Psychiatry 2005;62:37-45.
70. Brown ES. Bipolar disorder and substance abuse. Psychiatr Clin North Am 2005;28:415-25.